NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
05 October 2024
| Name: | DIMERIX LIMITED (DXB) | ||||||||||||
| ISIN: | AU000000DXB7 | ||||||||||||
| Date of Listing: | 04 February 1993 | ||||||||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 001 285 230ABN: 18 001 285 230
Registration Date: 13 May 1975
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| DIMERIX LIMITED | 01/12/2015 | |
| SUN BIOMEDICAL LIMITED | 19/12/2007 | 01/12/2015 |
| HARRINGTON GROUP LIMITED | 09/05/1997 | 19/12/2007 |
| AUSFOR LIMITED | 09/05/1997 |
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Dimerix Limited ("˜DXB') will be lifted immediately following the release by DXB of an announcement regarding a capital raising. | 04/05/2023 |
The company releases an Investor Presentation. | 04/05/2023 |
The company releases a notice of proposed issue of securities. | 04/05/2023 |
Dimerix is seeking to raise $12 million, through a combination of an entitlement offer and convertible notes, with an option for up to a further $8.5 million in convertible notes. The entitlement offer seeks to raise up to approximately $8.56 million through a partially underwritten non-renounceable entitlement offer to shareholders of 1 New Share for every 3 Shares held by eligible shareholders on the Record Date at an issue price of $0.08 per New Share. Approximately $4.06 million of the entitlement offer is underwritten. Every two shares under the Entitlement Offer will be accompanied by two free-attaching options in total. Commitment for full entitlement uptake and sub-underwriting of a portion of shortfall from substantial shareholder Mr Peter Meurs and directors Dr Nina Webster and Dr Sonia Poli. Firm sub-underwriting commitments from international institutional and sophisticated investors. Funds raised to continue the Company's Phase 3 FSGS clinical program past 1st interim data, including clinical, manufacturing and partnering activities. Dimerix has entered into a Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC, a US-based investment fund to access up to $12 million of funding, with an initial tranche of $3.5 million ($1.9 million of which is subject to shareholder approval) and a further optional tranche of up to $8.5 million by mutual agreement. | 04/05/2023 |
The securities of Dimerix Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of DXB, pending the release of an announcement regarding a capital raise. | 03/05/2023 |
The suspension of trading in the securities of Dimerix Limited will be lifted immediately, following receipt of an announcement regarding the proposed capital raising undertaken by the Company. | 06/12/2017 |
The company releases a notice to shareholders regarding the non-renounceable entitlement offer. Dimerix is pleased to confirm it has received firm commitments to participate in the Entitlement Offer from major shareholders, Directors and management to the amount of at least $800,000. | 06/12/2017 |
An entitlement offer booklet was also released by the company. | 06/12/2017 |
The company releases an entitlement offer cleansing notice in relation to the 1 for 2 offer. | 06/12/2017 |
The company intends to undertake a 1 for 2 pro rata non-renounceable entitlement offer of fully paid ordinary shares in Dimerix to raise approximately $5,524,906. The offer price for the Entitlement Offer will be 12 cents per New Share. The Entitlement Offer Price represents a 31% discount to the 15 day VWAP to 30 November 2017 of Dimerix shares. | 06/12/2017 |
The securities of Dimerix Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement. | 05/12/2017 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 31/10/2017 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 31/10/2017 |
name changed from Sun Biomedical Limited | 01/12/2015 |
The suspension of trading in the securities of Dimerix Limited ("˜DXB') will be lifted immediately following the release by DXB of an announcement regarding a capital raising. | 04/05/2023 |
The company releases an Investor Presentation. | 04/05/2023 |
The company releases a notice of proposed issue of securities. | 04/05/2023 |
Dimerix is seeking to raise $12 million, through a combination of an entitlement offer and convertible notes, with an option for up to a further $8.5 million in convertible notes. The entitlement offer seeks to raise up to approximately $8.56 million through a partially underwritten non-renounceable entitlement offer to shareholders of 1 New Share for every 3 Shares held by eligible shareholders on the Record Date at an issue price of $0.08 per New Share. Approximately $4.06 million of the entitlement offer is underwritten. Every two shares under the Entitlement Offer will be accompanied by two free-attaching options in total. Commitment for full entitlement uptake and sub-underwriting of a portion of shortfall from substantial shareholder Mr Peter Meurs and directors Dr Nina Webster and Dr Sonia Poli. Firm sub-underwriting commitments from international institutional and sophisticated investors. Funds raised to continue the Company's Phase 3 FSGS clinical program past 1st interim data, including clinical, manufacturing and partnering activities. Dimerix has entered into a Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC, a US-based investment fund to access up to $12 million of funding, with an initial tranche of $3.5 million ($1.9 million of which is subject to shareholder approval) and a further optional tranche of up to $8.5 million by mutual agreement. | 04/05/2023 |
The securities of Dimerix Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of DXB, pending the release of an announcement regarding a capital raise. | 03/05/2023 |
The suspension of trading in the securities of Dimerix Limited will be lifted immediately, following receipt of an announcement regarding the proposed capital raising undertaken by the Company. | 06/12/2017 |
The company releases a notice to shareholders regarding the non-renounceable entitlement offer. Dimerix is pleased to confirm it has received firm commitments to participate in the Entitlement Offer from major shareholders, Directors and management to the amount of at least $800,000. | 06/12/2017 |
An entitlement offer booklet was also released by the company. | 06/12/2017 |
The company releases an entitlement offer cleansing notice in relation to the 1 for 2 offer. | 06/12/2017 |
The company intends to undertake a 1 for 2 pro rata non-renounceable entitlement offer of fully paid ordinary shares in Dimerix to raise approximately $5,524,906. The offer price for the Entitlement Offer will be 12 cents per New Share. The Entitlement Offer Price represents a 31% discount to the 15 day VWAP to 30 November 2017 of Dimerix shares. | 06/12/2017 |
The securities of Dimerix Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement. | 05/12/2017 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 31/10/2017 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 31/10/2017 |
name changed from Sun Biomedical Limited | 01/12/2015 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 27/03/2024 | Nina Webster | 33,000 | $0.310 | $10,230 |
| 07/09/2018 | Nina Webster | 45,000 | $0.110 | $4,950 |
| 25/05/2018 | David Franklyn | 200,000 | $0.100 | $20,000 |
| 24/05/2018 | James Williams | 50,000 | $0.100 | $5,000 |
| 28/02/2017 | Sonia Poli | 2,600,000 | $0.008 | $20,800 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Mark Diamond | Chairman | 01/12/2023 |
| Sonia Poli | Managing Director | 05/07/2015 |
| Nina Webster | Managing Director, CEO | 27/08/2018 |
| Hamish George | CFO, Company Secretary | 06/05/2019 |
| Clinton Snow | Non Exec Director | 01/05/2023 |
| Hugh Alsop | Non Exec Director | 01/05/2017 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| James Williams | Non Exec Chairman | 26/11/2015 | 23/12/2022 |
| David Franklyn | Non Exec Director | 24/11/2015 | 11/10/2019 |
| Kathy Harrison | COO | 07/11/2016 | 30/11/2018 |
| Liz Jazwinska | Non Exec Director | 17/12/2015 | 03/11/2016 |
| Howard Digby | Executive Chairman | 22/01/2013 | 24/11/2015 |
| Anton Uvarov | Executive Director | 20/11/2013 | 24/11/2015 |
| Evan Cross | Non Exec Director | 01/03/2012 | 05/07/2015 |
| Peter Webse | Non Exec Director | 22/01/2013 | 03/07/2015 |
| Terry Cuthbertson | Non Exec Director | 02/09/2009 | 19/09/2013 |
| Peter Herd | Independent Director | 01/10/2009 | 22/01/2013 |
| Gary Stewart | Non Exec Director | 29/01/2010 | 22/01/2013 |
| Peter King | Executive Chairman | 24/02/2005 | 30/10/2010 |
| Jim Hallam | 24/10/2007 | 03/10/2009 | |
| Andrew Paice | CFO | 05/06/2006 | 04/09/2009 |
| Brian Andrews | Managing Director | 05/06/2006 | 24/02/2008 |
| Peter Bartleet | Non Exec Director | 26/02/2004 | 22/06/2007 |
| Peter Boonen | Executive Director | 30/08/2005 | 22/06/2007 |
| Taylor Fogelquist | COO | 04/02/2005 | 07/06/2006 |
| Chris Nichols | Non Exec Director | 04/02/2005 | 07/06/2006 |
| Michael Silver | Non Exec Director | 11/07/2001 | 14/12/2005 |
| Franco Canturi | Non Exec Director | 29/09/2003 | 13/02/2005 |
| Anthony Silver | Non Exec Director | 13/02/2005 | |
| Lindsay Sanford | Non Exec Director | 22/01/2003 | 01/10/2003 |
| William Tien | Non Exec Director | 14/02/2003 | 19/07/2003 |
| Gary A. Williams | Non Exec Director | 13/06/2002 | 08/03/2003 |
| Michael Ivkovic | Managing Director | 31/01/2001 | 24/01/2003 |
| David H. Brook | Non Exec Director | 09/11/1992 | 13/07/2001 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
